pitavastatin

The authors lead with the example of pitavastatin.

NPR Topics: News 2011

These data demonstrate sustained efficacy of pitavastatin over the long-term.

Presseportal redaktion@presseportal.de 2010

Kowa received FDA approval of pitavastatin (LIVALO (R)) for the treatment of primary hypercholesterolaemia and combined dyslipidaemia in August 2009 and it will be launched in the U.S. in June 2010.

Presseportal redaktion@presseportal.de 2010

In much of Europe, pitavastatin will be marketed by Recordati.

Presseportal redaktion@presseportal.de 2010

"This study confirms that pitavastatin is an effective and well tolerated long-term treatment option for patients with hypercholesterolaemia or combined dyslipidaemia," commented Dr. Leiv Ose, MD PhD, Rikshospitalet, Oslo University Hospital, Norway, and Study Investigator.

Presseportal redaktion@presseportal.de 2010

Wokingham, England, April 28, 2010 (ots/PRNewswire) - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and

Presseportal redaktion@presseportal.de 2010

On completion of the two studies, 1353 patients (42. 5% males/57. 5% females; mean age 58.6 years) took part in this open-label extension study to assess the long-term safety and tolerability of pitavastatin 4mg QD for up to 52 weeks; secondary objectives were to assess NCEP and EAS LDL-C target attainment, other lipid and lipoprotein fractions.

Presseportal redaktion@presseportal.de 2010

"With sustained efficacy, low rates of discontinuations due to adverse events and continued increases in HDL-C observed over 52 weeks, pitavastatin could provide clinicians with a new option in the long-term treatment of patients with hypercholesterolaemia or combined dyslipidaemia."

Presseportal redaktion@presseportal.de 2010

(TEAE) was related to pitavastatin, with the most commonly reported TEAEs being increased blood creatinine kinase (5. 8%), nasopharyngitis (5. 4%) and myalgia (4. 1%).

Presseportal redaktion@presseportal.de 2010

Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure.

Presseportal redaktion@presseportal.de 2010